Klin Farmakol Farm. 2007;21(2):84-86
Current and future treatment of cystic fibrosis
- 1 Pediatrická klinika 2. LF UK a FN Motol, Praha
- 2 Oddělení TRN, FN Praha Motol
- 3 Pneumologická klinika 2. LF UK a FN Motol, Praha
The aim of new methods in cystic fibrosis treatment is to supplement not to replace classical cystic fibrosis treatment. New methods of therapy are focused on modifying the quality of mucus by means of altered ion transport, suppressing infection and fighting inflammation. Searching for, preventing, and treating complications are important parts of the treatment. There is a general consensus that modern intensive centralized therapy will improve not only the survival but also the quality of life of cystic fibrosis patients.
Keywords: cystic fibrosis, anti-microbial therapy, anti-inflammatory agents, pancreatic substitution, new pharmacological approaches
Published: October 1, 2007 Show citation
References
- Vávrová V a kolektiv. Cystická fibróza. Praha: Grada, 2006:516.
- Bush A, Alton EWFW, Davies JC, Griesenbach U, Jaffe A, eds. Cystic fibrosis in the 21the century, Progress in respiratory research vol. 34. Basel: Karger, 2006:329.
Go to original source... - Pons G, Marchand MC, d'Athis P et al. French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The Amiloride-AFLM Collaborative Study Group. Pediatr Pulmonol. 2000; 30: 25-31. Go to original source...
Go to PubMed... - Tomkiewicz RP, App EM, De Sanctis GT et al. A comparison of a new mucolytic N-acetylcysteine L-lysinate with N-acetylcysteine: airway epithelial function and mucus changes in dog. Pulm Pharmacol 1995; 8: 259-265. Go to original source... Go to PubMed...
- Suri R, Marshall LJ, Wallis C, Metcalfe C, Bush A, Shute JK. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. Am J Respir Crit Care Med 2002; 166: 352-355. Go to original source... Go to PubMed...
- Noone P, Foy C, Shaffer C et al. Dose-effect for a novel P2Y2 agonist (INS37217) to induce chloride secretion across normal and CF airway epithelia. Pediatr Pulmonol 2003; Suppl. 25: P 185.
- Zeitlin PL, Boyle MP, Guggino WB, Molina L. A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest 2004; 125: 143-149. Go to original source... Go to PubMed...
- Hopkins S. Development of long acting sodium channel blockers for the treatment of cystic fibrosis lung disease. Pediatr Pulmonol 2003; Suppl. 25: 122-123.
- Cheng Y, Mishra A, Adebamiro A, Sjodin H, Bertrand CA, Bridges RJ. A novel extracellular protease mediated mechanism for the regulation of airway epithelial sodium transport. Pediatr Pulmonol. 2003; Suppl. 25: 120.
- Tullis E, Aaron S, Allard C et al. A randomized, double-blind, placebo controlled study of the effect of aerosolized low molecular weight dextran (DCF 987) on pulmonary function in adults with cystic fibrosis. Pediatr Pulmonol 2003; Suppl. 25: P 201.
- Cantin AM, Berthiaume Y, Cloutier D, Martel M. Prolastin aerosol therapy and sputum taurine in cystic fibrosis. Clin Invest Med 2006; 29: 201-207.
- Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. Highdose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A. 2006; 103: 4628-4633. Go to original source... Go to PubMed...
- Balfour-Lynn IM, Mohan U, Bush A, Rosenthal M. Intravenous immunoglobulin for cystic fibrosis lung disease: a case series of 16 children. Arch Dis Child 2004; 89: 315-319. Go to original source... Go to PubMed...
- Ledson M, Gallagher M, Hart CA, Walshaw M. Nebulized heparin in Burkholderia cepacia colonized adult cystic fibrosis patients. Eur Respir J 2001; 17: 36-38. Go to original source... Go to PubMed...